Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy

2.1 Olaparib (Lynparza, AstraZeneca) as tablets is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for olaparib.

2.3 The list price for olaparib tablets is £2,317.50 per 14‑day pack (56 × 150 mg tablets); £4,635.00 per 28‑day cycle (excluding VAT; BNF online, accessed March 2023).

2.4 The company has a commercial arrangement. This makes olaparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.